Delivery Order SPE2DB22D3004-SPE2DB25FRP65
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for 4,568,984,056 units of UBRELVY 100 mg tablets in unit dose packages of 16 tablets, valued at $59,129.24. This competitively awarded, firm fixed-price delivery order has an ultimate completion date of August 5, 2025, and is being fulfilled from the vendor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, and this delivery order represents fulfillment...
- The Defense Logistics Agency awarded a delivery order valued at $29,146.75 to AmerisourceBergen Drug Corp for UBRELVY 100 MG tablets (16-count unit dose packaging) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be fulfilled at the contractor's facility in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication, reflecting AmerisourceBergen's role as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,217.32 to AmerisourceBergen Drug Corp for UBRELVY 50 mg tablets (10 unit dose packages) on August 8, 2025, with an ultimate completion date of August 11, 2025. This firm fixed price delivery order represents a non-set-aside competitive award and reflects the pharmaceutical distribution services AmerisourceBergen provides to federal medical procurement. The place of performance is located in Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of UBRELVY 50 mg tablets in unit-dose packaging (10 units per package). This competitive award, valued at $30,906.84, represents a firm fixed-price delivery order with an ultimate completion date of July 25, 2025. The contract carries no set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order valued at $2,199.96 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit dose packages) on August 14, 2025, with an ultimate completion date of August 15, 2025. This is a firm fixed price delivery order with no set-aside designation, awarded competitively under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) vehicle with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and running through December...
- The Defense Logistics Agency awarded a $4,831.85 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 100 mg tablets in unit dose packaging (10 tablets per dose). This is a firm fixed-price delivery order with no set-aside designation, representing a competitively awarded contract. The order is scheduled for completion by July 29, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of UBRELVY 50 mg tablets in unit dose packaging (10 count). This order, valued at $5,439.62 with a firm fixed price structure, represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, with a...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,270.92 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10-count unit dose packaging) with an ultimate completion date of August 1, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded through an open process. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a migraine treatment medication,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets in unit dose packages of 10, valued at $1,595.01. This competitively awarded, firm fixed-price delivery order was issued on July 24, 2025, with an ultimate completion date of July 25, 2025. The contract involves no set-aside designation and identifies AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania as the place of performance. This delivery order...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,109.38 to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (10 unit-dose packages), with completion scheduled for August 1, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. UBRELVY is a prescription medication used for migraine treatment, representing one of numerous...
- SPE2DB22D3004Indefinite Delivery Contract
- SPE2DB22D3004-SPE2DB25FRP65Delivery Order
The Defense Logistics Agency awarded a $26,179.43 delivery order to AmerisourceBergen Drug Corp for UBRELVY 100 mg tablets (16-count unit dose packaging) on July 23, 2025, with completion scheduled for July 24, 2025. This competitively awarded, firm fixed-price contract represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. UBRELVY is a preventive migraine medication, and this procurement supports the federal military healthcare supply chain managed through DLA's Medical Supply division. AmerisourceBergen, a major pharmaceutical distributor and critical federal medical vendor, regularly fulfills such orders across its extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies. As the prime contractor on this delivery order with no set-aside designation, AmerisourceBergen demonstrates its continued capability to meet federal pharmaceutical procurement requirements through competitive solicitation and expedited delivery timelines.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $26.2k | 7/23/25 |